535 related articles for article (PubMed ID: 22644560)
21. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level.
Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh B; Kapoor R; Gupta R
Nucl Med Commun; 2011 Sep; 32(9):789-93. PubMed ID: 21760561
[TBL] [Abstract][Full Text] [Related]
24. Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer.
Vallam KC; Guruchannabasavaiah B; Agrawal A; Rangarajan V; Ostwal V; Engineer R; Saklani A
Colorectal Dis; 2017 Oct; 19(10):907-911. PubMed ID: 28444968
[TBL] [Abstract][Full Text] [Related]
25. Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations.
Zhang Y; Feng B; Zhang GL; Hu M; Fu Z; Zhao F; Zhang XL; Kong L; Yu JM
World J Gastroenterol; 2014 Jun; 20(21):6608-14. PubMed ID: 24914384
[TBL] [Abstract][Full Text] [Related]
26. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
Flanagan FL; Dehdashti F; Ogunbiyi OA; Kodner IJ; Siegel BA
Ann Surg; 1998 Mar; 227(3):319-23. PubMed ID: 9527052
[TBL] [Abstract][Full Text] [Related]
27. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence.
Makis W; Kurzencwyg D; Hickeson M
Clin Imaging; 2013; 37(6):1094-7. PubMed ID: 23993799
[TBL] [Abstract][Full Text] [Related]
29. Role of FDG-PET/CT in detection of recurrent disease in colorectal cancer.
Shamim SA; Kumar R; Halanaik D; Shandal V; Reddy RM; Bal CS; Malhotra A
Nucl Med Commun; 2010 Jun; 31(6):590-6. PubMed ID: 20300042
[TBL] [Abstract][Full Text] [Related]
30. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A
Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
[TBL] [Abstract][Full Text] [Related]
31. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
32. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
33. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
34. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
[TBL] [Abstract][Full Text] [Related]
35. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
36. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
Ozkan E; Soydal C; Araz M; Aras G; Ibis E
Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
38. The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.
Li W; Yin W; Ou R; Chen T; Xiong L; Cheng D; Xie D; Zheng X; Xu Y; Zhao L
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):675-81. PubMed ID: 26497700
[TBL] [Abstract][Full Text] [Related]
39. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
40. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
